Clariane SE (FRA:KO2) EBIT: €315 Mil (TTM As of Dec. 2025)


FRA:KO2 Clariane SE FRA:KO2
61 GF Score
Price €4.14
GF Value €2.46
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Clariane SE EBIT?

Clariane SE FRA:KO2 +1.62% 61 EBIT is €315 Mil as of Dec. 2025. GuruFocus rates FRA:KO2 with a GF Score™ of 61/100 and a GF Value™ of €2.46 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Clariane SE's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €236 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €315 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Clariane SE's annualized ROC % for the quarter that ended in Dec. 2025 was 1.63%. Clariane SE's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 7.31%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Clariane SE's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 3.58%.


Clariane SE  (FRA:KO2) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Clariane SE's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=274.552 * ( 1 - 16.27% )/( (14435.491 + 13715.551)/ 2 )
=229.8823896/14075.521
=1.63 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14411.116 - 866.971 - ( 751.746 - max(0, 2984.452 - 2093.106+751.746))
=14435.491

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=13806.87 - 792.111 - ( 821.556 - max(0, 2432.63 - 1731.838+821.556))
=13715.551

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Clariane SE's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=472.768/( ( (6519.609 + max(-586.838, 0)) + (6419.606 + max(-755.412, 0)) )/ 2 )
=472.768/( ( 6519.609 + 6419.606 )/ 2 )
=472.768/6469.6075
=7.31 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(483.824 + 37.367 + 473.79) - (866.971 + 0 + 714.848)
=-586.838

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(410.527 + 36.226 + 198.64) - (792.111 + 0 + 608.694)
=-755.412

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Clariane SE's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=314.906/8791.757
=3.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clariane SE EBIT Related Terms


Clariane SE EBIT Historical Data

* Premium members only.

The historical data trend for Clariane SE's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clariane SE EBIT Chart

Clariane SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 323.62 253.84 201.73 289.62 314.91

Clariane SE Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.17 135.95 153.67 78.52 236.38

FRA:KO2 vs HCA, THC, DVA: EBIT Comparison

For the Medical Care Facilities subindustry, Clariane SE's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clariane SE EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Clariane SE's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Clariane SE's EV-to-EBIT falls into.


FRA:KO2
61GF Score
Clariane SE FRA:KO2
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clariane SE EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €315 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €315 Mil mean?
Clariane SE (FRA:KO2) has a EBIT of €315 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Clariane SE.
Is Clariane SE's EBIT too high?
Clariane SE's current EBIT is €315 Mil. Overall, Clariane SE has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's EBIT compare to HCA and THC?
Clariane SE's EBIT of €315 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Clariane SE. Clariane SE's current EBIT is €315 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (FRA:KO2) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.46, compared to a current price of €4.14 — trading 68.3% above its estimated fair value. The current EBIT is €315 Mil. Clariane SE's overall GF Score™ is 61/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Clariane SE (FRA:KO2), the current EBIT is €315 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clariane SE (FRA:KO2) Overvalued in 2026?

Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued. The current stock price of €4.14 is trading 68.3% above its estimated GF Value™ of €2.46. GuruFocus considers Clariane SE to be Significantly Overvalued.

Key valuation signals for FRA:KO2:

  • EBIT: €315 Mil
  • GF Value™: €2.46 vs. price of €4.14 (68.3% above fair value)
  • GF Score™: 61/100 with 9 warning signs

No single metric tells the full story. See the FRA:KO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Clariane SE Business Description

Address 21-25, Rue Balzac, Paris, FRA, 75008
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
61GF Score

Get the complete analysis for FRA:KO2

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.14
Price
€2.46
GF Value